WARREN, N.J., (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH)  announced the closing of its previously announced public offering and concurrent registered direct offering for gross proceeds of approximately $43.7 million, which includes the full exercise of the underwriters’ option to purchase additional shares.

Bellerophon intends to use the net proceeds from the Offerings, together with its current cash and cash equivalents, for funding its ongoing clinical trials, working capital needs and other general corporate purposes.

Jefferies LLC acted as sole book-running manager for the Underwritten Offering. H.C. Wainwright & Co., LLC acted as the lead manager for the Underwritten Offering.

About Bellerophon

Bellerophon is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases and infectious lung diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system.